statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill...

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

Latest Ratings for ABBV
 DateFirmActionFromTo Feb 2022UBSDowngradesBuyNeutral Feb 2022MizuhoMaintainsBuy Feb 2022BarclaysMaintainsEqual-Weight
 View More Analyst Ratings for ABBV

 View...

Peeling Back The Layers: Exploring AbbVie Through Analyst Insights

The Arthritis Drug Faces Rising Competition

 Jamie Kelter Davis / Bloomberg via Getty Images

 Key TakeawaysAbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will...

AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump

AbbVie raised its full year profit guidance today, even as sales of its flagship medication have continued to fall. Read more...

AbbVie's newer drugs are offsetting losses of the world's once best-selling medication

AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That...

AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That

AbbVie lifts profit forecast after Skyrizi sales beat expectations...

AbbVie lifts profit forecast after Skyrizi sales beat expectations

AbbVie Reports First-Quarter 2024 Financial Results AbbVie Reports First-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., April 26, 2024 Reports First-Quarter Diluted EPS of $0.77 on a...

AbbVie Reports First-Quarter 2024 Financial Results

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
read more...

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

New Data Show RINVOQ (upadacitinib) Demonstrated Superiority Versus DUPIXENT (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study New Data Show...

New Data Show RINVOQ (upadacitinib) Demonstrated Superiority Versus DUPIXENT (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic...

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Volume	18.00
52-Wk High	$182.89
52-Wk Low	$130.96

ABBV Abbvie Inc

About

Feed

News

Sentiment

Earnings

Fundamentals